GQ1b-Seronegative Miller Fisher Syndrome Associated with Pembrolizumab
J Neuro-Ophthal 39:394-396, Green, K.E.,et al, 2019
Acute demyelinating polyneuropathy induced by nivolumab
JNNP 89:435-437, Fukumoto, Y.,et al, 2018
Acute Demyelinating Polyneuropathy Caused by Nivolumab in a Man with Metastatic Non-Small Cell Lung Cancer
J Gerontol Geriatr Res 5:3, Sabeeh-Ur-Rehman, B. & Bhaumik, S., 2016
The Acquired Metabolic Disorders of the Nervous System, Ischemic-Hypoxic Encephalopathy
Adams & Victors Principles of Neurology Chp 40, pg 1133, Ropper, A.H.,et al, 2014
Neurological Immune-Related Adverse Events of Ipilimumab
Pract Neurol 13:278-280, Bot, I.,et al, 2013
Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008
Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?
Arch Neurol 56:1028-1032, Karussis,D.&Abramsky,O., 1999
Childhood Leukemia:Central Nervous System Abnormalities During and After Treatment
AJNR 17:295-310, Chen,C-Y.,et al, 1996
Elevated Serum Levels of Tumor Necrosis Factor-a in Guillain-Barre Syndrome
Ann Neurol 33:591-596, 5631993., Sharief,M.K.,et al, 1993
Treatment of Guillain-Barre Syndrome with Anti-T Cell Monoclonal Antibodies
JNNP 54:51-54, Feasby,T.E., 1991
Guillain-Barre Syndrome after Myocardial Infarction
BMJ 294:613-614, McDonagh,A.J.G.&Dawson,J., 1987
Causes of Recurrent Laryngeal Nerve Paralysis
Arch Otolaryngol 102:259-261, Titche,L.L., 1976